COX- 2- hæmmere mindsker dannelsen af systemisk (og derfor muligvis endotelial) prostacyclin uden at påvirke trombycytternes tromboxan.
COX-2 inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.